PCSK9 Inhibitors: What Lies Beyond Monoclonal Antibodies?
出版信息
EBioMedicine. 2015 Dec 12;2(12):1835. doi: 10.1016/j.ebiom.2015.12.006. eCollection 2015 Dec.
Abstract
摘要
相似文献
1
PCSK9 Inhibitors: What Lies Beyond Monoclonal Antibodies?前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂：单克隆抗体之外还有什么？
EBioMedicine. 2015 Dec 12;2(12):1835. doi: 10.1016/j.ebiom.2015.12.006. eCollection 2015 Dec.
2
[Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target].[与低密度脂蛋白（LDL）相关的胆固醇及血管风险降低。前蛋白转化酶枯草溶菌素/kexin 9型（PCSK9）：一个新的治疗靶点]
Med Clin (Barc). 2015 Jul 20;145(2):67-9. doi: 10.1016/j.medcli.2015.04.007. Epub 2015 May 23.
3
[PCSK9 monoclonal antibody inhibition: current evidence and future perspectives of lipid-lowering therapy according to the available results from the ODYSSEY program].[前蛋白转化酶枯草溶菌素9单克隆抗体抑制作用：根据ODYSSEY项目现有结果看降脂治疗的当前证据及未来展望]
G Ital Cardiol (Rome). 2015 Apr;16(4):211-6. doi: 10.1714/1848.20182.
4
PCSK9 inhibitors are go.前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂已获批使用。
Nat Rev Drug Discov. 2015 Sep;14(9):593. doi: 10.1038/nrd4730.
5
6
PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges.用于治疗高胆固醇血症的前蛋白转化酶枯草溶菌素9（PCSK9）抑制：前景与新出现的挑战
Vascul Pharmacol. 2014 Aug;62(2):103-11. doi: 10.1016/j.vph.2014.05.011. Epub 2014 Jun 9.
7
[First PCSK9 inhibitor].[首个前蛋白转化酶枯草溶菌素9抑制剂]
MMW Fortschr Med. 2016 Jun 23;158(12):74.
8
[First PCSK9 inhibitor].[首个前蛋白转化酶枯草溶菌素9抑制剂]
MMW Fortschr Med. 2016 Jun 23;158(12):74. doi: 10.1007/s15006-016-8459-7.
9
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.前蛋白转化酶枯草溶菌素 9（PCSK9）抑制与降脂治疗的未来。
Prog Cardiovasc Dis. 2015 Jul-Aug;58(1):19-31. doi: 10.1016/j.pcad.2015.04.004. Epub 2015 May 1.
10
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.用于治疗高胆固醇水平的前蛋白转化酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂：有效性和价值。
JAMA Intern Med. 2016 Jan;176(1):107-8. doi: 10.1001/jamainternmed.2015.7248.
引用本文的文献
1
The Causal Relationship between PCSK9 Inhibitors and Malignant Tumors: A Mendelian Randomization Study Based on Drug Targeting.前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂与恶性肿瘤之间的因果关系：一项基于药物靶向的孟德尔随机化研究
Genes (Basel). 2024 Jan 21;15(1):132. doi: 10.3390/genes15010132.
Zotero 插件